
AcouSort to supply Lund University with unique pre-focusing technology to enable high precision cell separation

AcouSort has received an order from Lund University to develop and deliver a modified AcouWash2 system with a unique pre-focusing feature to enable high precision cell separation of circulating tumor cells from white blood cells. The project will generate revenue of SEK 500,000 in 2023.

By using pre-focusing technology, the modified AcouWash system will enable high precision separation of cells that are very similar in size and weight. This will in turn allow for a range of new applications to be developed for research and diagnostics purposes. One ambition is to develop a diagnostic application that can identify cancer cells at a very early stage, something which has the potential of increasing survival among cancer patients. Another ambition of the project is to develop a research application that can separate different types of white blood cells from each other enabling the analysis of the different populations separately.

“Working with customers within the academia is very important to AcouSort. From a global perspective, the commercial potential is substantial, but that is just one reason why these customers are attractive to us. By partnering with leading universities, we also gain a lot of knowledge as we constantly are pushed to advance our unique technology further,” says AcouSort’s CEO Torsten Freltoft.

For further information on AcouSort, please contact:

Torsten Freltoft, CEO

Telephone: +45 2045 0854

E-mail: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: certifiedadviser@penser.se Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.